OPIANT PHARMACEUTICALS, INC.
OPIANT PHARMACEUTICALS, INC. (OPNT): 6 pipeline candidates · ~23 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
23.0 months
D/E 1.05 · 0% dilution
Lead: Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for OPIANT PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$35.4M
Quarterly Burn
$4.7M
Runway
23.0 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Frequently asked questions
How many drug candidates are in OPIANT PHARMACEUTICALS, INC.'s pipeline?
OPIANT PHARMACEUTICALS, INC. (OPNT) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is OPIANT PHARMACEUTICALS, INC.'s lead drug candidate?
OPIANT PHARMACEUTICALS, INC.'s most advanced tracked candidate is drinabant (Preclinical) for Acute Cannabinoid Overdose.
What is OPIANT PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, OPIANT PHARMACEUTICALS, INC. has approximately 23.0 months of cash runway.
Who is the CEO of OPIANT PHARMACEUTICALS, INC.?
Roger Crystal Dr is the chief executive officer of OPIANT PHARMACEUTICALS, INC. (OPNT).
Get the full picture on OPIANT PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.